Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials

作者：Charlotte-Paige Rolle, José Ramón Arribas, Roberto Ortiz, Mark Underwood, Chris M. Parry, Richard Grove, V. Paul DiMondi, Bryn Jones, Michelle Kisare · 发表于：Open Forum Infectious Diseases · 年份：2025 · DOI：10.1093/ofid/ofaf135 · 被引用次数：2 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、Biochemical and Molecular Research

Abstract Through 144 weeks in GEMINI-1/-2 and 48 weeks in STAT, dolutegravir/lamivudine demonstrated high rates of virologic efficacy and a good safety profile in individuals naive to antiretroviral therapy across baseline viral load categories, including in those with very high baseline viral load (≥500 000 copies/mL). Clinical Trials Registration. NCT02831673/NCT02831764; NCT03945981.